Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Director Rostislav Christov Raykov sold 10,000 shares of the business's stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of C$7.46, for a total transaction of C$74,550.00.
Rostislav Christov Raykov also recently made the following trade(s):
- On Wednesday, March 5th, Rostislav Christov Raykov sold 7,569 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$9.71, for a total value of C$73,503.54.
- On Wednesday, February 5th, Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$9.66, for a total value of C$23,476.17.
Fennec Pharmaceuticals Stock Performance
Shares of Fennec Pharmaceuticals stock traded up C$0.03 during midday trading on Friday, hitting C$7.05. The company had a trading volume of 100 shares, compared to its average volume of 1,361. The stock has a market cap of C$135.96 million, a price-to-earnings ratio of -119.43 and a beta of 0.25. Fennec Pharmaceuticals Inc. has a 12-month low of C$5.65 and a 12-month high of C$14.32. The company has a quick ratio of 10.17, a current ratio of 7.80 and a debt-to-equity ratio of -620.83. The company has a fifty day simple moving average of C$9.04 and a 200 day simple moving average of C$8.12.
Fennec Pharmaceuticals Company Profile
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
See Also
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
